Analyze DCF forecasts for the company and compare them with competitors.
32.16B
Better than CX's revenue of 720.27M.
12.30%
Better than CX's revenue growth rate of 12.17%.
5.16B
Better than CX's ebitda of 139.02M.
16.04%
Worse than CX's ebitda margin of 19.30%.
3.55B
Better than CX's ebit of 83.57M.
11.03%
Worse than CX's ebit margin of 11.60%.
1.61B
Worse than CX's depreciation of 55.45M.
6.00B
Better than CX's total cash of 30.35M.
18.67%
Better than CX's cash as percentage of revenue of 4.21%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
3.75B
Worse than CX's inventories of 62.43M.
11.66%
Worse than CX's inventories as percentage of revenue of 8.67%.
2.83B
Worse than CX's accounts payable of 136.75M.
8.80%
Better than CX's payables as percentage of revenue of 18.99%.
-1.61B
Better than CX's capital expenditure of -49.16M.
-5.02%
Worse than CX's capex as percentage of revenue of -6.83%.
9.67%
Worse than CX's weighted average cost of capital (wacc) of 9.50%.
10.90%
Worse than CX's cost of equity of 9.69%.
4.40%
Better than CX's cost of debt of 7.04%.
1.38
Worse than CX's beta of 1.12.
729.20M
Better than CX's diluted shares outstanding of 1.47B.
13.52B
Worse than CX's total debt of 404.20M.
68.33B
Better than CX's total equity of 8.15B.
81.85B
Better than CX's total capital of 8.55B.
16.51%
Worse than CX's debt weighting of 4.73%.
83.49%
Worse than CX's equity weighting of 95.27%.
2.79B
Better than CX's ebiat of 67.52M.
2.86B
Better than CX's unlevered free cash flow of 63.26M.
2.00%
Equal to CX's long-term growth rate of 2.00%.
56.34B
Better than CX's terminal value of 942.19M.
50.68B
Better than CX's enterprise value of 835.36M.
6.94B
Worse than CX's net debt of 373.30M.
43.74B
Better than CX's equity value of 462.06M.
59.98
Better than CX's equity value per share of 0.31.
Analyze analyst forecasts for the company and compare them with competitors.
38.39B
Better than CX's estimated revenue of 17.01B.
6.05B
Better than CX's estimated ebitda of 2.47B.
5.53
Worse than CX's estimated eps of 12.47.
3.97B
Worse than CX's estimated net income of 18.33B.
3.91B
Better than CX's estimated ebit of 1.16B.
8.60B
Worse than CX's estimated sg&a expense of 3.20B.
View analysts' price targets and recommendations, and compare them with competitors.
$114.00
Lower downside than CX's downside of 16.39%.
Buy
Better than CX's analyst recommendation of Hold.
111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
